Celltrion Misses Market Consensus Despite Double-Digit Growth in Q3 2025 Earnings
Celltrion’s third-quarter 2025 earnings showed solid growth but missed market expectations, as higher sales of biosimilars and new drugs offset one-off impacts from divestments.